MEK inhibitor-associated retinopathy (MEKAR) is an umbrella term specifically used to include various entities that have been previously used to describe retinal adverse effects linked to MEK inhibitors, including serous retinopathy (SR), central serous retinopathy (CSR), serous retinal detachment (SRD), macular edema, visual disturbance, chorioretinopathy, and blurred vision [3,45,48]. This evidence concerns the gene MAP2K7 and central serous retinopathy.